Novaliq’s innovative EyeSol® technology is based on novel and exclusive water-free excipients.
It opens open completely new and intriguing opportunities to cure, relief and prevent diseases in various indications.
the technology is clinically proven to be safe and effective
EyeSol® substances are highly biocompatible and do not accumulate in human tissues
the technology platform is proprietary to Novaliq and IP protected
rich Pipeline with first- and best-in-class candidates for a variety of ocular and non-ocular therapies
For our products we only use highly pure substances and raw materials from qualified manufacturers. We have extensively tested and proven their safety, efficacy and tolerability in close cooperation with the regulatory authorities in Europe and USA, both preclinically and clinically.